You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer

  • Authors: Sara A. Hurvitz, MD; Hope S Rugo, MD
  • CME / ABIM MOC Released: 12/21/2016
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 12/21/2017, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

The goal of this activity is to increase understanding about the role of biologic therapies, and the potential role of novel biosimilars, in the care for patients with human epidermal growth factor receptor 2 (HER2)+ breast cancer across the disease spectrum.

Upon completion of this activity, learners will have:

  1. Increased knowledge regarding the clinical trial evidence of biologics and biosimilars in the management of HER2-positive breast cancer across the continuum of disease
  2. Greater competence related to the selection of evidence-based regimens for patients with HER2- positive breast cancer


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator(s)

  • Sara A. Hurvitz, MD, FACP

    Director, Breast Cancer Clinical Research Program, Associate Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

    Disclosures

    Disclosure: Sara A. Hurvitz, MD, FACP, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Cascadian, Genentech, Inc., GlaxoSmithKline, Lilly, Mediavation Inc., Merrimack, PUMA,

    Dr Hurvitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Hurvitz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Hope S. Rugo, MD

    Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Disclosures

    Disclosure: Hope S. Rugo, MD, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Genomic Health
    Received grants for clinical research from: Amgen Inc., BioMarin Inc., Eisai Inc., Genentech, Inc., GlaxoSmithKline, Lilly, Macrogenics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI, Pfizer Inc., Plexxikon

    Dr Rugo does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Rugo does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Roderick A Smith, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Roderick A Smith, MS, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Amy H. Seung, PharmD, BCOP

    Disclosures

    Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements


Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer

Authors: Sara A. Hurvitz, MD; Hope S Rugo, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/21/2016

Valid for credit through: 12/21/2017, 11:59 PM EST

processing....

 

  • Print